Prognostic Significance of Thymidylate Synthase Expression in Patients with Prostate Cancer Undergoing Radical Prostatectomy

Urology

Volumn 69, Issue 5, 2007, Pages 988-995

  Li, Yongnan ^a   Mizutani, Yoichi ^a   Shiraishi, Takumi ^a   Okihara, Koji ^a   Ukimura, Osamu ^a   Kawauchi, Akihiro ^a   Nonomura, Norio ^b   Fukushima, Masakazu ^c   Sakai, Toshiyuki ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; HORMONE; PYRIMIDINE NUCLEOTIDE; THYMIDYLATE SYNTHASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

AGED; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247582265     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.02.015     Document Type: Article

References (26)

1. Kuzel T., Tallman M., Shevrin D., et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois Cancer Center study. Cancer 72 (1993) 1965-1968
2. Birtle A.J., NewBy J.C., and Harland S.J. Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer 91 (2004) 1472-1476
3. Atkins J., Muss H.B., Case D., et al. High-dose 24 hour infusion of 5-fluorouracil in metastatic prostate cancer: a phase II trial of the Piedmont Oncology Association. J Clin Oncol 14 (1996) 526-529
4. Foekens J.A., Romain S., Look M.P., et al. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61 (2001) 1421-1425
5. Johnston P.G., Fisher E.R., Rockette H.E., et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12 (1994) 2640-2647
6. Correale P., Del Vecchlo M.T., Di Genova G., et al. 5-Fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 97 (2005) 1437-1445
7. Lenz H.J., Danenberg K.D., Leichman C.G., et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival and site. Clin Cancer Res 4 (1998) 1227-1234
8. Leichman C.G., Lenz H., Leichman L., et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infused fluorouracil and weekly leucovorin. J Clin Oncol 15 (1997) 3223-3229
9. Johnston P.G., Lenz H.J., Danenberg K.D., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55 (1995) 1407-1412
10. Huang C.L., Yokomise H., Kobayashi S., et al. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17 (2000) 47-54
11. Jakob C., Liersch T., Meyer W., et al. Immunochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer: correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemotherapy. Am J Surg Pathol 29 (2005) 1304-1309
12. Mizutani Y., Wada H., Ogawa O., et al. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92 (2001) 510-518
13. Mizutani Y., Wada H., Yoshida O., et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 9 (2003) 1453-1460
14. Gospodarowicz M.K., Miller D., Groome P.A., et al. The process for continuous improvement of the TNM classification. Cancer 100 (2004) 1-5
15. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
16. Nozawa H., Tsukui H., Nishida K., et al. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother Pharmacol 49 (2002) 267-273
17. Babaian R.J., Troncoso P., Bhadkamkar V.A., et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91 (2001) 1414-1422
18. Diasio R.B., and Lu Z. Dhydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12 (1994) 2239-2242
19. Kornmann M., Schwabe W., Sander S., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9 (2003) 4116-4124
20. Ichikawa W., Uetake H., Shirota Y., et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9 (2003) 786-791
21. Ogasawara Y., Doihara H., Shiroma K., et al. Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice. Surg Today 29 (1999) 149-156
22. Hung C., Liu D., Masuya D., et al. Clinical application of biological markers for treatment of respectable non-small-cell lung cancers. Br J Cancer 92 (2005) 1231-1239
23. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
24. Mizutani Y., Wada H., Yoshida O., et al. Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase in grade 1 and 2 superficial bladder cancer. Oncol Rep 9 (2002) 289-292
25. Fleming R.A., Milamo G., Thyss A., et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52 (1992) 2899-2902
26. Mizutani Y., Wada H., Yoshida O., et al. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur J Cancer 39 (2003) 541-547